Plain-English translation of NCT07391215 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new medication called combined with temozolomide (a standard chemotherapy) in people with glioblastoma, an aggressive type of brain cancer. The study focuses on patients whose tumors have specific genetic changes that might make them respond better to this combination. Researchers want to see if adding to the usual treatment helps people live longer and have better outcomes.
Glioblastoma is a very serious brain cancer that is difficult to treat, and many patients don't survive long even with current standard treatments. This trial exists because laboratory research suggests that this medication might work against the specific genetic mutations found in some glioblastomas, potentially offering patients a better treatment option.
You likely qualify if…
You likely don't qualify if…
You would take as a daily pill (starting at 45 mg, potentially increasing to 60 mg in the second month) combined with temozolomide chemotherapy taken by mouth for 5 days every 28 days. The trial has two phases: the first phase tests safety and finds the right dose, while the second phase looks at how well the combination works. You'll have regular blood tests, brain scans, and clinic visits to monitor your health and how your tumor is responding.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
United Kingdom